**Clean copy of claims for US Serial No 10/083,529**

**8.** (new) A method of potentiating anti-angiogenic substances by the use of Poly Unsaturated Fatty Acids (PUFAs) for treating hepatocellular carcinoma, comprising:

using a combination of selected PUFA/PUFAs and a lithium salt with an anti-angiogenic substance; and,

administering said combination by one or different routes selected from a group consisting of oral, parenteral, intravenous, subcutaneous, intra-peritoneal, topical, anal, vaginal and local injection.

**9.** (new) The method as in claim 8 wherein said anti-angiogenic substance is selected from ANGIOSTATIN and ENDOSTATIN, and said selected PUFA is chosen from a group consisting of: linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid.

**10.** (new) The method as in claim 8 including using a lymphographic agent with said PUFAs.

**11.** (new) A method of selectively inhibiting endothelial cell proliferation and causing necrosis of tumor-cells by delivering a selected combination of Poly Unsaturated Fatty Acid (PUFA) in conjugation with a lithium salt, a lymphographic agent and an anti-angiogenic substance chosen from ANGIOSTATIN and ENDOSTATIN, the method including the step of administering said combination by one or different routes chosen from a group consisting of oral, parenteral, intravenous, subcutaneous, intra-peritoneal, topical, anal, vaginal and local injection.

**12.** (new) The method as in claim 11, wherein said PUFA comprises one or more PUFAs selected from a group consisting of linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid.

**13.** (new) A method of treating mammalian cell proliferative disorder including Hodgkin's disease, comprising the steps of:
using an emulsion of a lithium salt of a Poly Unsaturated Fatty Acid chosen from linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid, and,
an anti-angiogenic protein/peptide substance.

**14.** (new) The method as in claim 13, wherein the anti-angiogenic substance is chosen from ANGIOSTATIN and ENDOSTATIN, said method including the step of administering said emulsion and the anti-angiogenic substance orally.

**15.** (new) The method as in claim 13, including the step of additionally using lymphokines and anti-cancer drugs, for treating said mammalian cell proliferative disorder.

**16.** (new) The method as in claim 15, wherein the lymphokines include TNF (Tumor Necrosis Factor) and IFN (Interferon).

**17.** (new) The method as in claim 15, wherein said anticancer drugs selectively comprise Doxorubicin and Vincristine.